121 related articles for article (PubMed ID: 35985203)
1. Anlotinib exerts potent antileukemic activities in Ph chromosome negative and positive B-cell acute lymphoblastic leukemia via perturbation of PI3K/AKT/mTOR pathway.
Chen Q; Lai Q; Jiang Y; Yao J; Chen Q; Zhang L; Wang C; Zhou Y; Deng M; Xu B
Transl Oncol; 2022 Nov; 25():101516. PubMed ID: 35985203
[TBL] [Abstract][Full Text] [Related]
2. Anlotinib Inhibits Proliferation and Induces Apoptosis in B-cell Acute Lymphoblastic Leukemia by Targeting the BTK and AKT/mTOR Pathway.
Shi X; Li S; Tang S; Lu Y
Anticancer Agents Med Chem; 2023; 23(12):1397-1405. PubMed ID: 36856175
[TBL] [Abstract][Full Text] [Related]
3. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
[TBL] [Abstract][Full Text] [Related]
4. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
[TBL] [Abstract][Full Text] [Related]
5. METTL3 suppresses anlotinib sensitivity by regulating m
Chen J; Li S; Huang Z; Cao C; Wang A; He Q
Cancer Cell Int; 2022 Sep; 22(1):295. PubMed ID: 36167542
[TBL] [Abstract][Full Text] [Related]
6. Anlotinib exerts an anti-T-cell acute lymphoblastic leukemia effect in vitro and in vivo.
Zhang X; Geng L; Yang L; Wang Y; Zou Z; Zhang Y; Xu H; Lei H; Cao Y; Wu Y; Gu W; Zhou L
Cell Signal; 2023 Oct; 110():110837. PubMed ID: 37544636
[TBL] [Abstract][Full Text] [Related]
7. Anlotinib Inhibiting Mantle Cell Lymphoma Proliferation and Inducing Apoptosis through PI3K/AKT/mTOR Pathway.
Wang J; Xu Z; Lai Y; Zhang Y; Zhang P; Mu Q; Yang S; Sheng L; Ouyang G
Curr Mol Med; 2024 Apr; ():. PubMed ID: 38659267
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.
Simioni C; Ultimo S; Martelli AM; Zauli G; Milani D; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2016 Nov; 7(48):79842-79853. PubMed ID: 27821800
[TBL] [Abstract][Full Text] [Related]
9. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Tasian SK; Teachey DT; Li Y; Shen F; Harvey RC; Chen IM; Ryan T; Vincent TL; Willman CL; Perl AE; Hunger SP; Loh ML; Carroll M; Grupp SA
Blood; 2017 Jan; 129(2):177-187. PubMed ID: 27777238
[TBL] [Abstract][Full Text] [Related]
10. Xihuang pills induce apoptosis in hepatocellular carcinoma by suppressing phosphoinositide 3-kinase/protein kinase-B/mechanistic target of rapamycin pathway.
Teng YJ; Deng Z; Ouyang ZG; Zhou Q; Mei S; Fan XX; Wu YR; Long HP; Fang LY; Yin DL; Zhang BY; Guo YM; Zhu WH; Huang Z; Zheng P; Ning DM; Tian XF
World J Gastrointest Oncol; 2022 Apr; 14(4):872-886. PubMed ID: 35582102
[TBL] [Abstract][Full Text] [Related]
11. Anlotinib as a promising inhibitor on tumor growth of oral squamous cell carcinoma through cell apoptosis and mitotic catastrophe.
Deng Z; Liao W; Wei W; Zhong G; He C; Zhang H; Liu Q; Xu X; Liang J; Liu Z
Cancer Cell Int; 2021 Jan; 21(1):37. PubMed ID: 33422069
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in
Zhang Q; Shi C; Han L; Jain N; Roberts KG; Ma H; Cai T; Cavazos A; Tabe Y; Jacamo RO; Mu H; Zhao Y; Wang J; Wu SC; Cao F; Zeng Z; Zhou J; Mi Y; Jabbour EJ; Levine R; Tasian SK; Mullighan CG; Weinstock DM; Fruman DA; Konopleva M
Oncotarget; 2018 Jan; 9(8):8027-8041. PubMed ID: 29487712
[TBL] [Abstract][Full Text] [Related]
13. Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade.
Yang Q; Ni L; Imani S; Xiang Z; Hai R; Ding R; Fu S; Wu JB; Wen Q
Cancer Manag Res; 2020; 12():4937-4948. PubMed ID: 32606981
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer.
Xia X; Pi W; Lan Y; Wu X; Lv D; Meng Y; Yang H; Wang W
Anal Cell Pathol (Amst); 2022; 2022():4484211. PubMed ID: 35757014
[TBL] [Abstract][Full Text] [Related]
15. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
[TBL] [Abstract][Full Text] [Related]
16. Anlotinib inhibits growth of human esophageal cancer TE-1 cells by negative regulating PI3K/Akt signaling pathway.
Liu Y; Li F; Wang Q; Zhang Y; Tian S; Li B
Discov Oncol; 2024 Apr; 15(1):134. PubMed ID: 38678128
[TBL] [Abstract][Full Text] [Related]
17. Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib.
Cao Y; Shan H; Liu M; Liu J; Zhang Z; Xu X; Liu Y; Xu H; Lei H; Yu M; Zhang X; Liu W; Bu Z; Fang Z; Ji Y; Yan H; Gu W; Wu Y
Cell Death Dis; 2021 Apr; 12(4):396. PubMed ID: 33854043
[TBL] [Abstract][Full Text] [Related]
18. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
[TBL] [Abstract][Full Text] [Related]
19. 20(S)-Ginsenoside Rh2 displays efficacy against T-cell acute lymphoblastic leukemia through the PI3K/Akt/mTOR signal pathway.
Xia T; Zhang J; Zhou C; Li Y; Duan W; Zhang B; Wang M; Fang J
J Ginseng Res; 2020 Sep; 44(5):725-737. PubMed ID: 32913402
[TBL] [Abstract][Full Text] [Related]
20. PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma.
Chen C; Guo Y; Huang Q; Wang B; Wang W; Niu J; Lou J; Xu J; Ren T; Huang Y; Guo W
Cancer Lett; 2022 Jun; 536():215660. PubMed ID: 35318116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
